Amicus Therapeutics Inc

Financials

Overview Finanzbericht Statistics Dividends

Cash from operating activities 233.29 M202.49 M166.57 M69.09 M33.89 M33.15 M 33.15 M Cash from investing activities 13.58 M78.76 M92.32 M98.06 M560 K46.43 M 46.43 M Cash from financing activities 262.86 M212.07 M7.46 M61.68 M5.12 M610 K 610 K Free cash flow 230.06 M198.61 M162.81 M61.65 M30.34 M29.85 M 29.85 M

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

FOLD

Financials

Amicus Therapeutics Inc

Nachrichten

Canaccord raises BioMarin stock price target to $104 on earnings

Celldex Therapeutics Stock Earns 88 RS Rating

BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market

BioMarin posts mixed Q4 results, shares edge lower

Sinkende Schätzungen vor BioMarin-Zahlen: Sorgen um Voxzogo belasten die Erwartungen

Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues

BioMarin earnings loom with estimates falling on Voxzogo worries

BB Biotech mit 660 % Gewinnplus in 2025 – Ausblick für 2026 jedoch verhalten

Amicus earnings on deck as $4.8B BioMarin deal awaits vote

What to Expect From These Drug/Biotech Players This Earnings Season?

BioMarin: Baird bleibt trotz Konkurrenzdruck bei neutraler Einstufung

Baird maintains BioMarin stock rating amid competitor’s positive trial data